Minimally Manipulated Allograft Fluids

For Inquries: Call (727) 456-8968

RELeV

RELeV is minimally manipulated allograft fluid with proven regenerative potential. The components in amnion are intended to maintain regenerative tissue processes.

Amniotic fluid contains growth factors, carbohydrates, proteins, amino acids and a multitude of essential molecules that are needed for tissue protection.

Why RELeV

  RELeV is intended to help with inflammation and to enhance the healing process.

  RELeV is immune-privileged; the risk of rejection is extremely rare

  For in-office procedures there is minimal, if any, down time after treatment.

  RELeV is typically a one-time treatment compared to corticosteroids which mask the pain by shutting down the body’s nerves in a specific area. Relief with steroids does begin right away but it does not last and there are significant sideeffects from long term use.

RELeV is recovered from healthy, carefully screened mothers at the time of cesarean section. All protocols are in accordance with the FDA and the American Association of Tissue Banks (AATB) regulations and standards. RELeV is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Services Act.

Potential Treatment Areas:

  Nerve Injury

  Degenerated Joints

  Ligament Tears

  Back Pain

  Joint Dysfunction

  Rotator Cuff Injury

  Cartilage Damage

  Knee Injuries

  Muscle Tears

RENuE

RENuE is a human tissue allograft derived from the umbilical cord and is intended for homologous use to supplement or replace damaged or inadequate connective tissue.

The cushioning and structural support elements from the Wharton’s Jelly consist of a network of structural proteins, cytokines, chemokines and growth factors. Wharton’s Jelly also has a much higher concentration of hyaluronic acid, cytokines, and growth factors when compared toAmniotic fluid, up to 50 times more. Hyaluronic acid is the key factor in the viscoelastic properties in synovial fluid or joints.

Why RENuE

  RENuE is less invasive when compared to other forms of regenerative medicine such as bone marrow aspirate and adipose tissue extraction. This results in less pain and rehabilitation time for the patient.

  Compared to amniotic fluid therapy, RENuE contains higher concentrations of hyaluronic acid, peptides and growth factors.

  Higher concentrations of growth factors in RENuE act as an anti inflammatory and have been shown to prevent cell death. *

RENuE is recovered from healthy, carefully screened mothers at the time of a scheduled cesarean section. All protocols are in accordance with the FDA and American Association of Tissue Banks (AATB) regulations and standards. RENuE is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.

*Sobolewski, K. et al. “Wharton’s Jelly as a reservoir of peptide growth factors.” Placenta. 2005 Nov; 26 (10): 747-52

Potential Treatment Areas:

  Aesthetics

  Degenerated Joints

  Ligament Tears

  Nerve Injury

  Back Pain

  Joint Dysfunction

  Meniscus Damage

  Rotator Cuff Injury

  Cartilage Damage

  Knee Injuries

  Muscle Tears

  Tendon Tears

RESToR

RESToR is a minimally manipulated allograft, derived from the umbilical cord tissue layer of Wharton’s Jelly, and processed to maximize concentration. RESToR is for homologous use and intended to enhance the body’s natural ability to heal.

Why RESToR

  RESToR works by secreting powerful bioactive molecules. RESToR contains a network of scaffolding proteins, growth factors, cytokines, mesenchymal stem cells and multiple other components needed to enhance the body’s natural ability to heal.

  RESToR umbilical cord tissues lack MHC-II and are therefore hypo immunogenic, consequently there is minimal risk of an allergic reaction for the recipient.

  RESToR has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.

  RESToR has a higher proliferation rate when compared to autologous tissue such as adipose or bone marrow.

  RESToR is less invasive when compared to other forms of regenerative medicine such as bone marrow and adipose tissue extraction; this results in less pain and rehabilitation time for the patient.

  RESToR is recovered from healthy, carefully screened mothers at the time of a scheduled cesarean section. All protocols are in accordance with the FDA and American Association of Tissue Banks (AATB) regulations and standards.

  RESToR is recovered from healthy, carefully screened mothers at the time of a scheduled cesarean section. All protocols are in accordance with the FDA and American Association of Tissue Banks (AATB) regulations and standards.

  RESToR is regulated as a human cell tissue product (HCT/P) under 21 CFR Part 127 and Section 361 of the Public Service Health Act.

Potential Treatment Areas:

  Aesthetics

  Degenerated Joints

  Ligament Tears

  Nerve Injury

  Back Pain

  Joint Dysfunction

  Meniscus Damage

  Rotator Cuff Injury

  Cartilage Damage

  Knee Injuries

  Muscle Tears

  Tendon Tears

REViV

REViV is a minimally manipulated human tissue allograft derived from the amniotic fluid and the extracellular matrix of the amniotic membrane. REViV is for homologous use and is intended to regulate and maintain tissue regenerative processes.

The extracellular matrix of REViV contains high concentrations of cellular scaffolding, cytokines, growth factors and proteins. The extracellular matrix (ECM) is a collection of extracellular molecules that provide the structural support needed for surrounding cells.

Amniotic ECM is comprised of collagens, multi-adhesive glycoproteins, elastic, glycosaminoglycans, growth factors and cytokines.

Why REViV

  REViV components are intended to reduce inflammation and continue the healing process, improving, or in some cases, eliminating your pain.

  REViV is immune-privileged; the risk of rejection is extremely rare

  For in-office procedures there is minimal, if any, down time after treatment.

  REViV is typically a one-time treatment compared to corticosteroids which mask the pain by shutting down the body’s nerves in a specific area. Relief with steroids does begin right away but it does not last and there are significant side-effects from long term use.

REViV is recovered from healthy, carefully screened mothers at the time of cesarean section. All protocols are in accordance with the FDA and the American Association of Tissue Banks (AATB) regulations and standards. REViV is regulated as a human cell, tisse, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.

Potential Treatment Areas:

  Aesthetics

  Degenerated Joints

  Ligament Tears

  Nerve Injury

  Back Pain

  Joint Dysfunction

  Meniscus Damage

  Rotator Cuff Injury

  Cartilage Damage

  Knee Injuries

  Muscle Tears

  Tendon Tears

Regenerative Medicine is Our Passion

Customer service available monday - friday - 9am - 5pm est.

© Copyright All rights reserved Genedix Lab 2018